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A 37-year-old who underwent splenectomy for motor vehicle accident-related injuries
was diagnosed with stage IIA carcinoma of left breast 12 years later. She underwent
bilateral mastectomy and bilateral immediate unipedicle TRAM ﬂap reconstruction.
Her preoperative platelet counts ranged from 332 to 424 K/cmm. Intraoperative ﬂuo-
rescein conﬁrmed mastectomy ﬂap viability. On postoperative day 1, platelet count was
374 K/cmm and all suture lines appeared benign. The patient was discharged 3 days
laterwithhealthy appearing tramﬂapsandslightepidermolysis intheabdominal region.
Over the next 2 weeks, both the mastectomy ﬂaps and the abdominal region underwent
progressive necrosis as the platelet count increased to 1390 K/cmm. Aspirin therapy was
institutedat this time.The TRAM ﬂaps remained completely viable. Eighteen days later,
the patient required wound debridement with secondary closure of the breast wounds.
Platelet count peaked at 1689 K/cmm 2 days later (postoperative day 38). The wounds
deteriorated again and were managed conservatively. Two months after mastectomy,
the ﬁrst area of spontaneous healing was documented (platelet count 758 K/cmm).
Ultimately, wounds healed as platelet count reached its preoperative baseline. We hy-
pothesize that an abnormal secondary thrombocytosis at subdermal plexus level caused
problematic healing in this patient’s mastectomy and abdominal ﬂaps.
Thrombocytosis, a condition in which there is an abnormally high number of circu-
lating platelets, can be described as either primary or secondary. Primary thrombocytosis
is usually associated with myeloproliferative disorders such as polycythemia vera and
essential thrombocythemia.1,2 Secondary thrombocytosis occurs after trauma, infection,
splenectomy, or as a reaction to drugs.3−5 In these situations, the platelet count routinely
increases at least 30%, peaking at 1 to 3 weeks and returning to normal over a period of
2 weeks to several months.6
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Traditionally, the risk of post-splenectomy thromboembolic phenomenon has been
considered quite low with few reports of complications appearing in the literature. Herein,
we report an unusual case of a young woman who underwent bilateral mastectomy with
immediate unipedicle TRAM ﬂap reconstruction and experienced progressive wound com-
plications associated with signiﬁcant platelet count increases.
CASE REPORT
A 25-year-old Caucasian female underwent a splenectomy which was performed through a
vertical midline incision in 1994 for injuries sustained in a motor vehicle collision. Twelve
years later, at age 37, she was diagnosed with stage IIA carcinoma of the left breast. She
presented for bilateral mastectomies with immediate autologous tissue reconstruction. She
had completed four cycles of neoadjuvant dose-dense adriamycin and cytoxan chemother-
apy 2 months previously. Following her chemotherapy, her platelet counts ranged from 332
to 424 K/cmm. Her medical history was signiﬁcant for obesity (BMI 40.4) and asthma. The
patient had smoked 1 pack per day for 15 years, but had discontinued that practice during
her chemotherapy treatment.
In 2006, she underwent a bilateral mastectomy with immediate bilateral ipsilateral
single pedicle transverse rectus abdominis myocutaneous (TRAM) ﬂap reconstruction. Ve-
nous thromboembolism prophylaxis was provided intraoperatively and during her hospital
stay via sequential compression devices (SCD). Although not a routine component of our
customaryreconstructions,ﬂuoresceinwasutilizedintraoperativelytoconﬁrmtheviability
of the mastectomy ﬂaps prior to ﬁnal insetting of the TRAM ﬂaps. The patient did well
during the procedure and suffered no intraoperative or postoperative hypotensive episodes.
Onpostoperativeday1,herwoundslookedwellandherplateletcountwas374K/cmm.She
was discharged on postoperative day 4 with slight epidermolysis in the abdominal ﬂap just
cephalad to the mid-line sutures. Over the next 2 weeks, both the mastectomy and abdom-
inal skin ﬂaps underwent progressive necrosis as the platelet count rose to 1390 K/cmm.
The patient’s hematologist/oncologist was consulted at this point. The consultant’s opinion
was that this was a reactive phenomenon and required no additional testing or intervention.
Even though the TRAM ﬂaps remained completely viable, aspirin therapy was instituted
empirically. The necrosis of the mastectomy and abdominal ﬂaps continued to evolve and
on postoperative day 18, the patient underwent operative debridement of her abdominal
(Fig 1) and chest wounds. The breast wounds were closed primarily and negative pressure
wound therapy (NPWT) was applied to her abdomen. Intraoperative ﬁndings conﬁrmed
extensive skin subcutaneous necrosis in the mastectomy and abdominal ﬂaps, whereas the
TRAM ﬂaps had minimal evidence of peripheral fat necrosis and no areas of skin loss. Her
platelet count peaked at 1689 K/cmm 2 days later. Over the next several weeks, the wounds
continued to deteriorate, but the patient elected to have them managed conservatively
(Fig 2). The patient was followed at weekly intervals in the outpatient clinic. Two months
after her original surgery the platelet count had decreased to 758 K/cmm, and the ﬁrst
area of spontaneous healing in the form of healthy granulation and wound contraction was
documented. Ultimately, the wounds healed by secondary intention (Fig 3) as the platelet
count returned to its postoperative nadir of 530.
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Figure 1. Preoperative view of necrotic abdominal wound.
DISCUSSION
Thrombocytosis is considered to exist when the concentration of circulating platelets
reaches 400 to 600 K/cmm.7,8 Although it has been suggested that platelet counts in
excess of 1 million/cm are necessary for hemorrhage and thrombotic sequelae,9 there is no
consensus on scientiﬁcally derived, evidence-based indications for antiplatelet therapy in
the perioperative period. In part, this may be due to a lack of correlation between platelet
counts and thrombocytosis.8,10−14
The surgical literature has implicated thrombocytosis as a potential etiologic fac-
tor in phlebitis and deep venous thrombosis (DVT),15 pulmonary embolism,16 mesenteric
ischemia,17,18 and cerebrovascular accidents9 and infarction.19 However, Kuo and col-
leagues found no evidence to suggest that thrombocytosis in and of itself had any negative
impact on microvascular patency rates in a splenectomy-induced thrombocytosis model.
Traditionally, therefore, presence of thrombocytosis had not warranted routine anticoagu-
lation prophylaxis.8
Recentstudieshaveinvestigatedthebiochemistryoftheplateletanditsresponseinthe
perioperative period. As early as the 1950s and 1960s, it was recognized that platelet levels
increased after surgery.20−22 Folman et al.23 identiﬁed thrombopoietin and other cytokines
as stimulators of postoperative thrombopoiesis. Yet it was not until the mid 1970s that the
functional status of the platelet was found to be an even more important factor than the
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Figure 2. Postoperative day 8 view of deteriorating wounds after debridement of abdominal and
chest wounds and closure of breast wounds.
absolute number. Matsuda et al.24 reported two cases of postoperative thrombocytosis in
whichtheplateletpopulationswerestudied.Byvirtueoftheirinvitroassays,theywereable
to identify two populations of platelets in the thrombocytotic postoperative situation. Each
population was associated with a distinct phase of aggregation, the secondary population
whose functions were much more enhanced than the ﬁrst. It was hypothesized that it
is this secondary population that is responsible for the postoperative thromboembolic
phenomenon. Interestingly, the enhanced functioning of this platelet group was easily
suppressed by the low-dose aspirin.
In light of the ﬁndings of a large multicenter trial that determined that aspirin did,
in fact, reduce the risk of pulmonary embolism and DVT after surgery,25 Matsuda et al.24
recommend that aspirin be employed to prevent signiﬁcant thromboembolic complications,
particularly when platelets are excessively produced and hyper-functioning. Twenty-ﬁve
years later, Kuo et al.7 echoed this sentiment by concluding that “a platelet activation
proﬁle study is even more important than platelet count alone in preoperative evaluation
of microvascular surgery cases. Once both thrombocytosis and platelet activation occur,
antiplatelet activation drugs are recommended.”
This patient had an uncomplicated mastectomy procedure and underwent intraopera-
tive ﬂuorescein testing to ensure the viability of all skin ﬂaps. Despite this maneuver, all of
thenativeskinﬂapsnecrosed,whilethemusculocutaneousﬂapssurvived.Althoughepider-
molysis was noted early in the postoperative period, extensive necrosis became evident as
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Figure 3. View of wounds after healing by secondary intention.
the platelet count exceeded 1000 K/cmm as suggested by Heller et al.9 Even though aspirin
therapy was instituted, the extensive nature of tissue necrosis required that the patient be
returned to the operating room for debridement. At the second procedure, all wounds were
debrided back to healthy, vascularized tissue. Despite this, all three wounds necrosed as
the platelet count peaked at 1689 K/cmm. UItimately, as the platelet count resolved, the
wounds responded to NPWT and healed by secondary intention. Since the TRAM ﬂaps
survived, we hypothesize that operative trauma to the small vessels in the skin ﬂap subder-
mal plexus caused an aggregation of an abnormally high number of platelets, a secondary
thrombocytosis, resulting in small vessel occlusion and subsequent skin necrosis. Should
this patient, or similar patients, require surgery in the future, a platelet activation proﬁle
study might be a valuable tool to assess the potential need for aggressive anti-platelet
therapy.
CONCLUSION
The series of events in this case may have resulted from abnormally robust platelet aggre-
gation (secondary thrombocytosis) at the subdermal plexus level in the most vulnerable
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